TRANSGENE (EPA:TNG) | Finanzwire

Basculer en Français

10481	Companies
220813	Keywords
150157	Articles
116811	Press releases

Home
Companies
TRANSGENE

BRIEF

published on 05/26/2026 at 08:05, 6 days 14 hours ago

Transgene to Unveil TG-MVA Vaccine Data at Infectious Diseases Congress

Preclinical Data Orthopoxvirus Transgene Mpox Vaccine MVA Technology
PRESS RELEASE

published on 05/26/2026 at 08:00, 6 days 14 hours ago

Transgene to Present Preclinical Data on Novel TG-MVA Prophylactic Vaccine Against mpox at the World Congress on Infectious Diseases
Transgene to present preclinical data on novel TG-MVA prophylactic vaccine against mpox at World Congress on Infectious Diseases. Focus on Orthopoxvirus-related diseases. Oral presentation by Head of Vectorology Laboratory, Nathalie Silvestre

Preclinical Data Mpox Transgene TG-MVA Prophylactic Vaccine
BRIEF

published on 05/22/2026 at 17:50, 10 days 4 hours ago

Results of the Transgene General Meeting of May 22, 2026

Independence General Assembly Medical Transgene Administrators
BRIEF

published on 05/22/2026 at 17:50, 10 days 4 hours ago

Transgene's General Meeting Approves Board Resolutions and New Appointments

Shareholder Approval General Meeting Director Appointments Board Resolutions Transgene
PRESS RELEASE

published on 05/22/2026 at 17:45, 10 days 4 hours ago

Transgene’s Combined General Meeting of May 22, 2026
Transgene's Combined General Meeting of May 22, 2026 in France concludes with approval of key resolutions and new independent Directors appointed

Shareholders General Meeting Directors Independent Transgene
BRIEF

published on 04/13/2026 at 08:05, 1 month 18 days ago

Transgene Concludes Patient Randomization in Phase 2 of TG4050 Clinical Trial

Phase 2 Clinical Trial Head And Neck Cancer Transgene TG4050 Vaccine Disease-free Survival
PRESS RELEASE

published on 04/13/2026 at 08:00, 1 month 18 days ago

Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer
Transgene completes patient randomization in Phase 2 of clinical trial for TG4050 in adjuvant treatment of head and neck cancer. Top-line results expected by Q1 2028

Clinical Trial Head And Neck Cancer Phase 2 Transgene TG4050
BRIEF

published on 04/02/2026 at 17:50, 1 month 29 days ago

Transgene and NEC Bio Forge Partnership for TG4050 Development

License Agreement Transgene Neoantigen Vaccine NEC Bio TG4050 Development
PRESS RELEASE

published on 04/02/2026 at 17:45, 1 month 29 days ago

Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer
Transgene and NEC Bio sign license agreement to advance development of TG4050 in head and neck cancer, leveraging AI technology for neoantigen selection

AI Technology Head And Neck Cancer Transgene TG4050 NEC Bio
BRIEF

published on 03/26/2026 at 17:50, 2 months 6 days ago

Transgene to Present TG4050 Vaccine Data at World Vaccine Congress

World Vaccine Congress Cancer Immunotherapy Transgene TG4050 Neoantigen Vaccine

1 2 ... 6

Accesswire

Published on 06/01/2026 at 22:01, 25 minutes ago

Unusual Machines Promotes Trish Ellis to Vice President of Human Resources
Published on 06/01/2026 at 21:25, 1 hour 1 minute ago

China Is Closing the Door on Heavy Rare Earth Exports for Good, NioCorp CEO Warns in Fox News Op-Ed
Published on 06/01/2026 at 18:30, 3 hours 56 minutes ago

Galaxy Ventures Inc. Enters into Definitive Agreement with TruSilver Metals Corp. to Complete Qualifying Transaction
Published on 06/01/2026 at 15:30, 6 hours 56 minutes ago

Karbon-X to Present at the Small Cap Growth Virtual Investor Conference June 4th
Published on 06/01/2026 at 14:30, 7 hours 56 minutes ago

Klondike Gold Announces Receipt of Funds from Gold Royalty Payments and Warrants Exercise

View all ACCESSWIRE

EQS Group

Published on 06/01/2026 at 22:05, 20 minutes ago

EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Published on 06/01/2026 at 22:05, 20 minutes ago

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis
Published on 06/01/2026 at 21:20, 1 hour 6 minutes ago

Eurobattery Minerals: Loft Capital exercises conversion rights – Conversion Threshold Date reached and a total of 23,798,419 new shares to be registered
Published on 06/01/2026 at 19:00, 3 hours 25 minutes ago

Armen Pogossian Represents Armenia at Forbes Under 30 Summit China, Empowering the Next Generation of Global Entrepreneurs
Published on 06/01/2026 at 17:50, 4 hours 36 minutes ago

Alta Group announcement on Voluntary Takeover Offers for Addiko Bank AG

Les Echos

Published on 06/01/2026 at 18:47, 3 hours 38 minutes ago

Disclosure of transactions in own shares from May 25 to May 29, 2026
Published on 06/01/2026 at 18:00, 4 hours 26 minutes ago

Covivio - Information on total number of voting rights and share capital
Published on 06/01/2026 at 17:54, 4 hours 31 minutes ago

Reporting on share buyback transactions carried out on May 28, 2026
Published on 06/01/2026 at 17:54, 4 hours 31 minutes ago

TF1 - Monthly disclosure of the total number of shares and voting rights - May 2026
Published on 06/01/2026 at 17:45, 4 hours 40 minutes ago

ENGIE secures €1 billion export financing backed by Euler Hermes

View all LES ECHOS COMFI WIRE